

## President's Message

*Linda Chang, MD, MS, SNIP President*

### In this issue:

- Welcome message
- President's message
- 2025 29<sup>th</sup> SNIP meeting summary, Omaha, NE
- ECITA winners and awardees
- NIPT, SNIP official journal
- Upcoming 2026 meeting
- Job portal

## Introduction

*by Santhi Gorantla, PhD,  
SNIP Communications,  
Chair*

Warm greetings and best wishes to all! This Spring 2026 issue of the *Society's Newsletter* is the official publication of SNIP and highlights the Society's recent activities, including summaries of past and upcoming meetings. In this issue, we feature a summary of the 29th SNIP Scientific Conference held in as well as news and announcements of broad interest to our members. Omaha, Nebraska; recognize the ECI travel awardees; provide updates from our official SNIP journal, *NIPT*; and announce details of the 2026 SNIP meeting. We extend our sincere gratitude to everyone who attended and contributed to the successful organization of the 2025 SNIP meeting in Omaha.

Following the resounding success of our 29<sup>th</sup> SNIP Conference in Omaha, Nebraska (June 7-11, 2025), I am pleased to build on our growth and honored to serve as the Society's president for 6/2025-5/2026. As one of the original founding members of SNIP, I learned so much and form invaluable collaborations with SNIP members over the years. SNIP has been a transformative influence for my career; therefore, it is only fitting that I repay the society by serving as the current president. Together with an outstanding council and the various committees, we pledge to build our society's legacy to ensure we hold yet another outstanding annual meeting to develop our mission, our membership and our trainees.

The 29<sup>th</sup> conference in Omaha, Nebraska, had a record high number of 222 attendees, including members and trainees, and 25 invited non-member speakers. In addition to the outstanding science presented, we provided 22 travel awards for our trainees. With additional funds raised by our Past President, Dr. Gendelman, the attendees were treated to an afternoon fun at the Omaha zoo and dancing with a live band after the banquet. (More about this conference on the following pages).

We have a diverse membership comprising preclinical and clinical translational scientists, with interdisciplinary expertise that form the rich and comprehensive symposia at our conferences. I have often heard from our members, who commented on how much they learned at each of our conferences. Furthermore, we put special emphasis on nurturing and supporting our next generation of scientists in our field. Hence, we provide many travel awards (22 travel awards in 2025) to encourage our trainees to attend our annual conferences. These travel awards were at times supported by R13 conference grants from the National Institutes of Health (NIH), especially from NIDA, NIMH and NINDS in the past. We also include in our program special sessions for early career investigator poster and oral presentations; these were always outstanding and extremely well attended.

For the upcoming 30<sup>th</sup> conference in Annapolis, Maryland, we received 185 abstracts which will be presented in 70 talks in two preconference symposia, 11 symposia during the conference and 115 posters in two poster sessions. We again provided 22 travel awards to the early career investigators (ECIs). We have an outstanding scientific program, and exceptional invited speakers, including Dr. Nora Volkow from NIDA and Dr. Avindra Nath from NINDS. Therefore, we expect another record-breaking attendance at our upcoming 30<sup>th</sup> SNIP conference.

In addition, we now have our society's official journal, which is led by our Editor-In-Chief, Dr. Howard Gendelman, who led our prior SNIP-associated journal, *Journal of NeuroImmune Pharmacology (JNIP)*, to outstanding impact factors. With the strong membership and the trainees from these laboratories, and open access to the journal, we have every reason to expect our new journal, ***Neuroimmune Pharmacology and Therapeutics (NIPT)***, to exceed the citations and impact of our prior journal. I encourage all of you to continue your support for this journal by submitting your best work to the journal.

On behalf of our society and our Council, we look forward to seeing you in Annapolis, Maryland for our 30<sup>th</sup> annual SNIP conference on May 3-6, 2026!




# 2025 SNIP Omaha Meeting Summary & Highlights

by *Santhi Gorantla, Ph.D.*

The 29th Scientific Conference of the Society on NeuroImmune Pharmacology (SNIP) convened June 8–11, 2025, in Omaha, Nebraska, bringing together an international community of neuroscientists, immunologists, pharmacologists, clinicians, and trainees to explore advances in neuroimmune mechanisms and translational medicine. The four-day meeting, was reported in *NeuroImmune Pharmacology and Therapeutics* (DOI: 10.1515/nipt-2025-0004). It is the only conference dedicated specifically to neuroimmune pharmacology and the neuroimmune axis in the context of substance use, inflammation, and brain infections, particularly HIV. The 29th Scientific Conference highlighted cutting-edge science spanning neurodegenerative disorders, substance use disorders, viral neuropathogenesis, and biomarker development.

Firstly, we gratefully acknowledge the generous support of **Dr. Carol Swarts, the Robert Eisenberg Family, Howard Kooper, the Gendelman Family Research Endowment, Fisher Scientific**, and the broader research community for sponsoring this meeting and enabling its rich scientific exchanges. We also recognize the exceptional leadership of **Howard E. Gendelman**, 2025 SNIP President, whose sustained efforts in securing substantial funding made it possible to host an outstanding program and invite a distinguished roster of eminent speakers. We thank Dr. Howard Gendelman and his secretary, Ms. Amy Sather, for their exceptional efforts in fully organizing and managing the 2025 SNIP Conference in Omaha. A special feature of this year's meeting was the SNIP banquet guest of honor, **Dr. Robert C. Gallo**, whose keynote address reflected on his life experiences and seminal discoveries in human retrovirology, inspiring attendees with both scientific insight and personal narrative. The conference integrated pre-conference workshops, symposia led by eminent scientists, early-career development sessions, and commemorative events to create a holistic environment for scientific exchange and professional growth.

The conference began with **two pre-conference workshops** designed to set thematic and professional tones. The workshop ***Creation, Care, and Translation of Humanized Mouse Models for HIV/AIDS Research*** presented by leading experts, **Angela Wahl, Jennifer Koblinski, Santhi Gorantla and Ramesh Akhina** covered next-generation humanized rodent platforms, care standards, and translational applications in neuroHIV and related research, and the roundtable was moderated by Paul Denton. A **second pre-conference workshop, *Mentoring and Opportunities for Early-Stage Investigators in Neuroscience (ESINs)***, was moderated by **Siddappa Byrareddy, PhD** with co-chairs **Vasudev Rao, PhD, William Daley, PhD, and Kathleen Borgmann, PhD**, representing NIMH, NINDS, and NIDA. Vinayaka R. Prasad provided an overview and networking session, while mentoring discussions were led by **Amanda Brown, PhD**. A round-table discussion with **Yisel M. Cantres-Rosario, PhD, Aditya Bade, PhD, Kathleen Borgmann, PhD and Siddappa Byrareddy, PhD** offered early-stage investigators guidance on career development, collaboration, and networking, emphasizing the importance of structured mentorship in neuroimmune pharmacology. The scientific program opened with the ***Presidential Symposium*** on Pathobiology and Novel Therapies for Neurodegenerative Diseases, chaired by **Howard E. Gendelman, MD**. Dr. Gendelman presented advances in next-generation cellular therapies, highlighting the development of engineered immune strategies such as CAR-T–based approaches targeting pathogenic proteins implicated in neurodegenerative disorders. **Serge Przedborski, PhD (Columbia University)**, provided an in-depth overview of the neuropathogenesis of degenerative diseases of the nervous system, emphasizing mitochondrial dysfunction, oxidative stress, and neuroimmune mechanisms driving neuronal loss. **Christopher Wheeler, PhD (T-Neuro Pharma)**, discussed the therapeutic potential of cytolytic T-cell targeting strategies in Alzheimer's disease, outlining emerging immunotherapeutic approaches aimed at modifying disease progression. **Susmita Sil, PhD (UNMC)**, presented work on monocyte-derived biomarkers for early-stage sargramostim therapy in Parkinson's disease. The ***Toby Eisenstein Memorial Lecture*** was delivered by **Mary Lou Falcone**, who shared personal reflections on caregiving from her work *I Didn't See It Coming*. A key quote reflecting her journey is: "You have to join the person where they are, you can't expect them to come to you in their former state. It is just not possible". ***Symposium 2 was on Ultra-Long-Acting Antiretroviral Drugs*** focused on transformative approaches in HIV therapeutics. **Charles Flexner, MD (Johns Hopkins University)**, described how long-acting antiretroviral formulations are revolutionizing HIV treatment and prevention, emphasizing improved adherence and global health impact. **Benson Edagwa, PhD (UNMC)**, highlighted advances in ultra-long-acting slow effective release (LASER) antiretroviral therapies, including drug-delivery systems designed to enhance tissue distribution and durability. **Jim Rooney, MD (Gilead Sciences)**, presented clinical developments surrounding Lenacapavir, a first-in-class long-acting capsid inhibitor with promising applications for both HIV treatment and prevention. **Paul L. Domanico, PhD (Clinton Health Access Initiative)**, discussed global health initiatives aimed at expanding equitable access to HIV therapies worldwide. ***The Drs. Mahendra and Adarsh Kumar Memorial Lecture*** was delivered by **Tsuneya Ikezu, MD, PhD (Mayo Clinic)**, who presented pioneering work demonstrating how cargo lipids in APOE4-associated extracellular vesicles promote tau propagation, offering new mechanistic insights into Alzheimer's



disease pathogenesis. The lunch symposium featured emerging investigators presenting diverse studies across neuroHIV and neurodegeneration. Presentations included metabolic pathway comparisons between Alzheimer's disease and neuroHIV (**Ali Boustani**), microbiome-driven neurobehavioral alterations (**Tabinda Salman**), and proteomic profiling of astrocyte-derived exosomes as biomarkers for HIV-associated neurocognitive impairment (**Lester Rosario Rodriguez**). Additional talks explored post-COVID structural brain abnormalities (**Meghann Ryan**), estrogen and fentanyl effects on HIV replication and immune migration across the blood–brain barrier (**Maya Basic**), and drug-induced modulation of microglial antiviral responses (**Tofunmi Oteju**). Research by Qianhao Xiao demonstrated that fentanyl enhances HIV infection in macrophages and microglia (**Suresh Kondeti**), while **Sandip Godse** discussed curcumin-based adjuvant strategies to improve HIV neurotherapy. Further talks examined monoaminergic transporter modulation by HIV-Tat-associated compounds, CRISPR-based HIV excision using myeloid-targeted lipid nanoparticles, glial recovery following antiretroviral therapy using single-cell RNA sequencing, and methamphetamine-mediated regulation of HIV integration and latency in microglia models.

Subsequent sessions explored translational neurotherapeutic strategies and brain delivery technologies. **Symposium 4: Development and Delivery of Diagnostic and Therapeutic Biomarkers to the Brain** included presentations by **Piotr Walczak, MD, PhD** on multimodal imaging approaches for targeted delivery of cells and biologics to the central nervous system, **Assaf Gilad, PhD** on bioengineered proteins for diagnostic and therapeutic applications, **Chengyan Chu, MD, MD** on intra-arterial drug delivery combined with osmotic blood–brain barrier opening, and **Wojciech Lesniak, PhD** on PET-based imaging of neuroinflammation and brain injury. **Symposium 5: Assessing the Blood–Brain Barrier in Neurological Disorders and Inflammation** highlighted the importance of vascular integrity in neuroimmune diseases. Presentations examined blood–brain barrier disruption signatures in HIV and cannabis use (**Jennifer Ludicello, PhD**), stroke vulnerability in the context of HIV infection (**Silvia Torices, PhD**), protective roles of microglia in maintaining blood–brain barrier integrity during aging (**Richard Milner, PhD**), antiretroviral drug effects on blood–brain barrier function (**Violaine Delorme-Walker, PhD**), and extracellular vesicle–mediated blood–brain barrier injury induced by alcohol and e-cigarette exposure (**Naveen Mekala, PhD**).



The **conference banquet** honored **Robert C. Gallo, MD**, whose keynote lecture traced the history and future of viral immunology, including his seminal contributions to the discovery of Human Immunodeficiency Virus and the development of modern retrovirology. The UNMC President Dr. **Jeffrey P. Gold, MD** introduced Dr. Gallo, who reflected on decades of scientific progress, the importance of global collaboration, and the role of mentorship in advancing biomedical discovery. The evening concluded with a live band performance that provided an opportunity for attendees to celebrate the conference in a fun and relaxed atmosphere.

On the final day, **Symposium 10: Advances in Informatics Analyses of Multi-Omics Data** showcased computational approaches to neuroimmune research. Presentations included studies on morphine-potentiated HIV Tat–mediated neuroinflammation (**Uma Maheswari Deshetty**), single-cell transcriptomic analysis of opioid-induced neuronal and glial changes (**Sabita Roy, PhD**), and cannabinoid-mediated reduction of viral reservoirs and inflammation (**Dionna Williams, PhD**).

The session concluded with the **Bill Narayan Memorial Lecture** by **Howard Fox, MD, PhD**, who discussed how multi-omics and data-driven science are transforming neuroimmune pharmacology. The **SNIP Member Symposium** and **Local Organizing Committee Symposium**, chaired by **Prasanta Dash, PhD** highlighted work from investigators at the University of Nebraska Medical Center. Presentations included accelerated neuroimmune dysregulation in HIV-infected aging humanized mice (**Prasanta Dash, PhD**), neurocardiac interactions in chronic heart failure (**Han-Jun Wang, MD**), pathogenic mechanisms linking neurodegeneration and substance use disorders (**Sowmya Yelamanchili, PhD**), molecular signatures in rebound viruses following antiretroviral therapy and CRISPR therapy (**Chen Zhang, PhD**), and aging-associated HIV reservoir dynamics (**Arpan Acharya, PhD**).

Across all sessions, mechanistic insights into neuroimmune regulation, viral persistence, and neurodegenerative processes were integrated with translational strategies targeting therapeutic development, biomarker discovery, and advanced drug-delivery technologies. The interdisciplinary integration of neuroscience, immunology, pharmacology, and clinical research remained a defining theme, reinforcing the mission of the Society on NeuroImmune Pharmacology to translate basic discoveries into meaningful clinical advances.

Early-career investigators were actively engaged throughout the meeting through poster sessions, oral presentations, mentoring luncheons, and grant-writing workshops with NIH program officers, fostering professional development and collaboration.

In conclusion, the 29th Scientific Conference of the Society on NeuroImmune Pharmacology successfully showcased cutting-edge research spanning neurodegeneration, HIV neuropathogenesis, addiction neuroscience, and translational therapeutics, bringing together leading investigators and emerging scientists to advance the field of neuroimmune pharmacology.

## 2025 SNIP Meeting Early Career Investigator Travel Awards (ECITA)

At each annual SNIP meeting, the Early Career Investigator Travel Award (ECITA) committee provides an outstanding platform for junior investigators to gain exposure, exchange ideas, and access resources essential for career advancement. ECITA has a long-standing tradition of supporting these “rising stars” through competitive travel awards that waive registration fees and/or provide travel support, while offering opportunities to disseminate their research through the Young Investigator Forum. The highest-scoring abstracts from both graduate students and postdoctoral fellows are selected for oral presentations, highlighting excellence in early career research. In addition, the ECITA committee hosts a mentor–mentee luncheon, fostering meaningful interactions with established investigators and providing valuable guidance for career development and long-term growth planning.

### The June 2025 29th SNIP ECITA- full award recipients are as follows:

No.	Name	Degree	Institution	Lab
1	Tabinda Salman	PhD	Medical University of South Carolina	Jiang Lab
2	Lester J. Rosario Rodriguez	PhD	University of Puerto Rico, Medical Sciences Campus	Wonja Lab
3	Meghann Ryan	BS	University of Maryland	Chang Lab
4	Maya Basic	BS	University of Florida	Andrews Lab
5	Tofunmmi Oteju	BS	Drexel University College of Medicine	Gaskill Lab
6	Qianhao Xiao	PhD	Temple University	Ho Lab
7	Sandip P. Godse	BS	University of Tennessee Health Science Center	Kumar Lab
8	Ana Catya de Jesus Jimenez Torres	PhD	University of South Carolina	Zhu Lab
9	Soumya Sagar Dey	BS	University of Nebraska Medical Center	Gendelman Lab
10	Suresh Kondeti	PhD	University of Nebraska Medical Center	Gorantla Lab
11	Wei Ling Lim	PhD	San Diego Biomedical Research Institute	Marcondes Lab
12	Ali Boustani	MD	University of California San Diego	Fields Lab
13	Daniella Levitis	BS	University of Miami Miller School of Medicine	Park Lab
14	Douglas Johnson	BS	Medical University of South Carolina	Jiang Lab
15	Ali Namvaran	PhD	University of Nebraska Medical Center	Bidasee Lab
16	Marzieh Daniali	BS	Drexel University	Gaskill Lab
17	Brent Bever	BS	Oregon Health and Science University	Lancioni Lab
18	Darius Quansah	BS	University of North Dakota	Geiger Lab
19	Mohammed Mehdi Benmassaoud	PhD	University of Florida	Andrews Lab
20	Jazelle Delaney	BS	University of South Carolina	Zhu Lab
21	Amanda Fernandes	BS	University of Nebraska Medical Center	Gorantla Lab
22	Bryant Avalos	PhD	University of California, San Diego	Fields Lab

## 2025 SNIP Meeting ECITA (Continued)

The ECITA and Best Poster Awards as well as the Society Awards were presented during the banquet:


Poster Award	Name	Training Level	Lab (PI)	Institution
First Place Postdoc Poster	Ali Namvaran, PhD	Postdoctoral Fellow	Keshore Bidasee Lab	University of Nebraska Medical Center
Second Place Postdoc Poster	Ana Jimenez Torres, PhD	Postdoctoral Fellow	Zhu Lab	University of South Carolina
First Place Predoc Poster	Jeremy Laws	PhD Student	Andrews Lab	University of Florida
Second Place Predoc Poster	Tofunmmi Oteju	PhD Student	Gaskill Lab	Drexel University College of Medicine

**2025 ECITA Awardees** - Picture taken with **Howard Gendelman, MD** (2025 SNIP President, left front), **Jerel Adam Fields, PhD** (Chair ECITA Committee, right back row) and **Robert C. Gallo, MD** (Banquet Speaker)



### 2025 Society Awards

- ❖ **Lifetime Service Award**  
Dr. Toby Eisenstein, Temple University (Post humously)
- ❖ **Herman Friedman Founder's Award**  
Dr. Santosh Kumar, University of Tennessee Health Science Center
- ❖ **Distinguished Service Award**  
Dr. Santhi Gorantla, University of Nebraska Medical Center
- ❖ **Outstanding Service and Support Award**  
Dr. Allison Andrews, University of Florida,



**NIPT is fee-free for one more year**

**This is the last (most crucial) year to submit your manuscripts to NIPT before the submission fees are active**

**Submit today!**

### **NeuroImmune Pharmacology and Therapeutics (NIPT)**

NeuroImmune Pharmacology and Therapeutics (NIPT) is the official peer-reviewed journal of the Society on NeuroImmune Pharmacology. Launched in early 2022 to reflect the Society's interdisciplinary mission, NIPT showcases cutting-edge research across four core areas: neuroscience, immunology, pharmacology, and therapeutics. Manuscripts are encouraged to focus on one or more of these disciplines and their intersections, advancing basic, clinical, and translational science.

NIPT is fully owned by the Society and is published as an open-access journal by De Gruyter (ISSN: 2750-6665), with online publication preceding print distribution by the University of Nebraska Press. The journal was founded by Dr. Howard Gendelman, who also organized and appointed the editorial board, and developed NIPT in collaboration with the Society, fellow editors, and philanthropic donors.

More than \$335,000 was raised to support the Journal, with principal contributions from Dr. Carol Swarts, along with additional financial support from Bob Eisenberg and Dr. Howard Gendelman himself. These philanthropic efforts have enabled key initiatives, including waivers and discounts for article processing charges (APCs). During the journal's first and second years, APCs were waived for invited contributions to special theme issues as well as for unsolicited manuscripts, and the article processing charges are also waived this year. Contributions from Society members continue to be welcomed and encouraged.

#### **Journal website**

<https://www.degruyter.com/journal/key/nipt/html>

#### **Submission portal**

<https://mc.manuscriptcentral.com/nipt>


#### **Contact NIPT**

For more information, please contact the journal's editorial office at [nipt@unmc.edu](mailto:nipt@unmc.edu)

## Upcoming Conference

**30th Scientific Conference — May 3-6th, 2026**

Annapolis, MD



<https://s-nip.org/conferences>

## 2026 Newly elected society council members



**President-Elect**  
Dr. Servio Ramirez



**Meetings, Chair**  
Richard Noel



**Communications, Chair**  
Dr. Santhi Gorantla



**Councilor-at-large**  
Dr. Peter Gaskill



**Councilor-at-large**  
Dr. Kelly Jordan-  
Sciutto



**Councilor-at-large**  
Dr. Jason Paris



**Adhoc Councilor**  
Dr. Wen-Zhe Ho

## Assistant/Associate/Full Professor- Basic Science

TT PhD Scientist: 26FA0147

<https://jobs.rutgers.edu/postings/269414>

RWJMS-Rutgers Institute for Translational Medicine and Science (RITMS), Center for HIV-Associated Co-Morbidities and Translational Science (CHACTS)

The Rutgers Institute for Translational Medicine and Science (RITMS) invites applications for tenure-track faculty positions at the Assistant, Associate, or Full Professor level. Successful candidates will join the Rutgers Center for HIV-Associated Co-Morbidities and Translational Science (CHACTS), located within the state-of-the-art Rutgers Helix research complex. CHACTS is dedicated to building a premier national research program focused on advancing transformative science at the intersection of HIV and associated co-morbidities within a leading academic medical center. CHACTS is uniquely structured to tackle the multifaceted challenges of HIV-related complications by fostering a highly collaborative and translational research environment that accelerates the conversion of laboratory findings into therapeutic strategies, reinforcing a core mission of improving health outcomes for people living with HIV.

We seek highly motivated and collaborative investigators, particularly those investigating mechanisms underlying HIV-associated cardiovascular, neurological, or metabolic complications. Faculty appointments will be made within appropriate Rutgers Robert Wood Johnson Medical School departments, such as Neuroscience and Cell Biology, Pharmacology, Medicine, or Infectious Diseases, and include access to robust graduate programs, interdisciplinary collaboration opportunities, and exceptional research infrastructure.

### Why Join Rutgers CHACTS?

#### Exceptional Research Environment

- Access to outstanding core facilities, including a modern vivarium with 24/7 activity monitoring systems, behavioral testing cores, and BSL-2/2+ laboratory and animal facilities, wet and dry laboratory spaces within the Helix research complex.
- Engagement in innovative research that links fundamental biological discovery to clinical relevance, with the goal of elucidating mechanisms that drive HIV-associated conditions such as cardiovascular disease, neurological and metabolic dysfunction, and mental health disorders

#### Competitive Support

- Generous start-up packages designed to accelerate new or expanding research programs.

#### Collaborative and Interdisciplinary Culture

- Work alongside prominent faculty in a highly supportive research ecosystem with strong institutional commitment to translational science.
- Diverse, interdisciplinary community of basic scientists and clinician-investigators

#### Access to Top Research Trainees

- CHACTS faculty recruit from multiple PhD programs including Neuroscience, Molecular Bioscience, Biomedical Engineering, Endocrinology & Animal Sciences, Behavioral Neuroscience, and Toxicology.
- Faculty also engage exceptional undergraduate researchers from Rutgers Honors College and life science majors.
- Rutgers' reputation, diverse community, and geographic location draw exceptional postdoctoral scholars from around the world.

#### Faculty Responsibilities

- Develop and maintain a nationally and internationally recognized, externally funded research program with strong translational and interdisciplinary impact.
- Collaborate with faculty across CHACTS, RITMS, RWJMS departments, Rutgers Health, and the wider university community.
- Participate in graduate and medical student education, including mentorship and research training.
- Contribute to the academic community through seminars, committee service, mentoring of junior faculty and trainees, and participation in institute-wide initiatives.

#### Compliance and Leadership Expectations

- Adhere to Rutgers' compliance standards: Corporate Compliance Policy, Code of Conduct, and Conflict of Interest policies.
- Maintain familiarity with evolving federal, state, and university regulations.
- Ensure that any supervised staff receive appropriate compliance training and evaluation.
- Demonstrate strong leadership, communication, and interpersonal skills; experience working in a unionized environment is preferred.

#### Compensation and Benefits

Final salary offers will consider the candidate's qualifications, experience, expertise, and available departmental or grant-supported resources. Rutgers may also consider market benchmarks and internal equity to maintain fair and competitive compensation.

Eligible employees receive a comprehensive Rutgers benefits package, which may include:

- Medical, prescription, dental, and life insurance coverage
- Competitive retirement plans and voluntary tax-deferred savings options
- Generous paid vacation, holidays, and other leave programs
- Tuition remission and educational benefits for employees and dependents
- Employee discount programs

Additional details regarding benefits and eligibility are available at the Rutgers employee benefits portal.

visit: <http://uhr.rutgers.edu/benefits/benefits-overview>.

Please send the following to [ritms@rbhs.rutgers.edu](mailto:ritms@rbhs.rutgers.edu):

1. Cover Letter/Letter of Application, 2. Resume/CV, 3. List of Professional References (contact Info), 4. Research Statement, and 5. Personal Statement.

## **Assistant/Associate/Full Professor- Clinical**

TT Physician Scientist: 26FA0151

<https://jobs.rutgers.edu/postings/269508>

RWJMS-Rutgers Institute for Translational Medicine and Science (RITMS), Center for HIV-Associated Co-Morbidities and Translational Science (CHACTS)

The Rutgers Institute for Translational Medicine and Science (RITMS) invites applications from accomplished physician-scientists (MD or MD/PhD) for tenure-track faculty positions at the rank of Assistant, Associate, or Full Professor. Successful candidates will join the Rutgers Center for HIV-Associated Co-Morbidities and Translational Science (CHACTS), located within the state-of-the-art Rutgers Helix research complex.

CHACTS is uniquely structured to address the multifaceted challenges of HIV-associated complications by bringing together a diverse community of basic, translational, and clinical researchers. Our interdisciplinary environment supports innovative research that bridges laboratory discovery with clinical practice, empowering faculty to identify the biological mechanisms driving HIV-related disorders, including cardiovascular disease, neurologic dysfunction, metabolic disturbances, and mental health complications and develop strategies that translate into improved outcomes for people living with HIV. By integrating both wet and dry laboratory research approaches, CHACTS provides a cohesive translational framework that moves discoveries seamlessly from bench to bedside and back again. This structure enhances collaboration, accelerates therapeutic development, and strengthens the potential for meaningful clinical impact.

We are seeking accomplished physician-scientists with an MD or MD/PhD, preferably with fellowship training or clinical expertise in Infectious Diseases, who are pursuing research into the mechanisms driving HIV-associated cardiovascular, neurological, or metabolic complications and their translation into clinical interventions. Faculty appointments will be made within appropriate Rutgers Robert Wood Johnson Medical School departments and divisions, such as Medicine and Division of Allergy, Immunology and Infectious Diseases, and include full access to graduate programs, interdisciplinary collaboration, and exceptional clinical and research infrastructure.

### **Why Join Rutgers CHACTS?**

#### **Exceptional Research Environment**

Access to outstanding core facilities, including a modern vivarium with 24/7 activity monitoring systems, behavioral testing cores, and BSL-2/2+ laboratory and animal facilities, wet and dry laboratory spaces within the Helix research complex.

Engagement in innovative research that links fundamental biological discovery to clinical relevance, with the goal of elucidating mechanisms that drive HIV-associated conditions such as cardiovascular disease, neurological and metabolic dysfunction, and mental health disorders

#### **Competitive Support**

Generous start-up packages designed to accelerate new or expanding research programs.

#### **Collaborative and Interdisciplinary Culture**

Work alongside prominent faculty in a highly supportive research ecosystem with strong institutional commitment to translational science.

Diverse, interdisciplinary community of basic scientists and clinician-investigators

#### **Access to Top Research Trainees**

CHACTS faculty recruit from multiple PhD programs including Neuroscience, Molecular Bioscience, Biomedical Engineering, Endocrinology & Animal Sciences, Behavioral Neuroscience, and Toxicology.

Faculty also engage exceptional undergraduate researchers from Rutgers Honors College and life science majors.

Rutgers' reputation, diverse community, and geographic location draw exceptional postdoctoral scholars from around the world.

#### **Faculty Responsibilities**

Develop and maintain a nationally and internationally recognized, externally funded research program with strong translational and interdisciplinary impact.

Collaborate with faculty across CHACTS, RITMS, RWJMS departments, Rutgers Health, and the wider university community.

Engage in medical and graduate education, including mentoring of trainees, residents, fellows, postdocs, and junior faculty.

Contribute to the broader academic community through seminars, committees, and Institute-wide initiatives.

#### **Compliance and Leadership Expectations**

Adhere to Rutgers' compliance standards, including the Corporate Compliance Policy, Code of Conduct, and Conflict of Interest policies.

Maintain familiarity with evolving federal, state, and university regulations.

Ensure that any supervised staff receive appropriate compliance training and evaluation.

Demonstrate strong leadership, communication, and interpersonal skills; experience working in a unionized environment is preferred.

#### **Compensation and Benefits**

Final salary offers will consider the candidate's qualifications, experience, expertise, and available departmental or grant-supported resources.

Rutgers may also consider market benchmarks and internal equity to maintain fair and competitive compensation.

Eligible employees receive a comprehensive Rutgers benefits package, which may include:

Medical, prescription, dental, and life insurance coverage

Competitive retirement plans and voluntary tax-deferred savings options

Generous paid vacation, holidays, and other leave programs

Tuition remission and educational benefits for employees and dependents

Employee discount programs

Additional details regarding benefits and eligibility are available at the Rutgers employee benefits portal.

visit: <http://uhr.rutgers.edu/benefits/benefits-overview>.

Please send the following to [ritms@rbhs.rutgers.edu](mailto:ritms@rbhs.rutgers.edu):

Cover Letter/Letter of Application

Resume/CV

List of Professional References (contact Info)